Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins

Cell Death and Differentiation

Volumn 14, Issue 9, 2007, Pages 1605-1616

  Wolter, K G ^a   Verhaegen, M ^a   Fernandez Y ^a,c   Nikolovska Coleska, Z ^b   Riblett, M ^a   Martin de la Vega, C ^a,d   Wang, S ^b   Soengas, M S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c MERCK KGAA   (Germany)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GOSSYPOL; PLACEBO; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RNA INTERFERENCE;

EID: 34548011015     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402163     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151.
3. Chin L, Garraway LA, Fisher DE. Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev 2006; 20: 2149-2182.
4. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004; 64: 4912-4918.
5. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL et al. Chemical blockage of the proteasome inhibitory function of bortozomib: Impact on tumor cell death. J Biol Chem 2006; 281 1107-1118.
6. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications. Cancer Res 2005; 65: 6294-6304.
7. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 2006; 66: 9635-9645.
8. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282-6293.
9. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
10. Fribley AM, Evenchik B, Zang Q, Park BK, Guan JY, Zhang H et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281: 31440-31447.
11. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257-264.
12. Naik E, Michalak EM, Villunger A, Adams JM, Strasser A. Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J Cell Biol 2007; 176. 415-424.
13. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival bcl-2 proloins by their BH3-only ligands allow complementary apoptotic function. Mol Cell 2005; 17: 393-403.
14. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
15. Markovic SN, Geyer SM, Dawkins F, Shartman W, Albertini M, Maples W et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005; 103: 2584-2589.
16. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002: 99: 14374-14379.
17. Herrant M, Jaquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863-7873.
18. Letal A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Cin Invest 2005; 115: 2648-2655.
19. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30: 133-142.
20. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419-1421.
21. Oitersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
22. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374-2380.
23. Dodou K, Anderson RJ, Small DA, Groundwater PW. Investigations on gossypol: Past and present developments. Expert Opin Investig Drugs 2005; 14: 1419-1434.
24. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139-6142.
25. Shelley MD, Hartley L, Fish RG, Groundwater P, Morgan JJ, Mort D et al. Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett 1999; 135: 171-180.
26. Blackstaffe L, Shelley MD, Fish RG. Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines. Melanoma Res 1997; 7: 364-372.
27. Tuszynski GP, Cossu G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res 1984; 44: 768-771.
28. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H et al. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 2006.
29. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
30. Verhaegen M, Bauer JA, Martin de la Vega C, Wang T, Wolter KG, Brenner JC et al. A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell survival controlled by p53 and reactive oxygen spaces. Cancer Res 2006, 66: 11348-11359.
31. Yamamura K, Kamada S, Ito S, Nakagawa K, Ichihashi M, Tsujimoto Y. Accelerated disappearance of melanocytes in bcl-2-deficient mice. Cancer Res 1996; 56: 3546-3550.
32. Olle RA, Hafner C, kuttel R, Sigrist B, Willers J, Dummer R et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002; 118 505-512.
33. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
34. Green DR. At the gates of death. Cancer Cell 2006; 9: 328-330.
35. Youle RJ. Cell biology: Cellular demolition and the rules of engagement. Science 2007; 315: 776-777.
36. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Huntingt) 2004; 18: 14-21.
37. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not bax or bak. Science 2007; 315: 856-859.
38. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
39. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348-1358.
40. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379.